Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
February 26, 2025
Kristian Larsen, Ulrich Lindberg, Brice Ozenne et al.
9 citations
Psilocybin, the active compound in magic mushrooms, reduces blood flow in the brain. In a study of 28 healthy volunteers, psilocybin decreased cerebral blood flow by about 11.6% at peak effect, while the serotonin blocker ketanserin had no significant effect. Psilocybin also constricted the internal carotid artery by 10.5%, whereas ketanserin did not. These findings suggest that psilocybin's effects on brain blood flow involve the serotonin 2A receptor and may help explain its therapeutic potential for conditions like depression.
Neuroscience Applied
December 30, 2023
Sophia Armand, Kristian Larsen, Martin K Madsen et al.
7 citations
The psychedelic drug psilocybin acutely reduces amygdala reactivity to angry faces in healthy individuals, while its subjective intensity is linked to reduced amygdala response to fearful faces. In 26 participants, fMRI scans showed that amygdala response to angry faces was significantly lower under psilocybin compared to baseline. No significant changes occurred for fearful or neutral faces. Higher subjective drug intensity was associated with weaker amygdala response to fearful faces, but plasma psilocin levels showed no such link. These findings align with prior work, suggesting psilocybin alters emotion processing in the brain, with potential implications for treating depression.
Journal of Cerebral Blood Flow & Metabolism
November 29, 2024
Frederick A. Bagdasarian, Kristian Larsen, Deng Hong et al.
1 citation
Psilocybin, lisuride, and 25CN-NBOH, three serotonin 2A receptor agonists with different pharmacological profiles, produce distinct brain blood flow patterns in anesthetized nonhuman primates. Psilocybin and lisuride, which are mixed partial agonists, caused biphasic cerebral blood volume changes, while the selective agonist 25CN-NBOH produced monophasic increases. Cortical receptor occupancy for psilocybin plateaued at 60 µg/kg (32%), similar to that of a lower dose of lisuride (31%). 25CN-NBOH had lower occupancy (7%) but larger blood volume changes. The relationship between blood volume and receptor occupancy appeared linear for lisuride and 25CN-NBOH but not for psilocybin. These differences may stem from the mixed affinity profiles of the agonists, providing insights for developing psychiatric therapeutics.
Figshare
January 1, 2026
Kristian Larsen
LSD and psilocybin produce distinct changes in cerebral blood flow and global functional connectivity across the human brain. Peak drug effects were observed in both measures, and within-subject associations between blood flow and connectivity were assessed using Spearman's rank correlation. The findings characterize how these hallucinogens alter brain activity at the population level in healthy participants.
Figshare
January 1, 2026
Kristian Larsen
Psilocybin reduces whole-brain cerebral blood flow and constricts the internal carotid artery in a dose-dependent manner. In 28 healthy participants given 0.2–0.3 mg/kg psilocybin, arterial spin labelling MRI showed widespread cortical blood flow decreases at peak plasma psilocin levels. Higher plasma psilocin concentrations correlated with lower cerebral blood flow and smaller carotid artery diameter, indicating that the drug's vascular effects are tied to its active metabolite.
Figshare
January 1, 2026
Kristian Larsen
LSD occupies the serotonin 2A receptor (5-HT2AR) and alters global functional connectivity in healthy human participants. The figure shows occupancy and connectivity effects for both LSD and psilocybin. Acquisition, preprocessing, and statistical modeling procedures were pre-registered and detailed in a study protocol.
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition
November 26, 2024
Ande Bagdasarian, Kristian Larsen, Patrick M. Fisher et al.
Psilocybin and lisuride produce a two-phase (bi-phasic) change in cerebral blood volume, while 25CN-NBOH produces a single-phase (monophasic) response. The bi-phasic pattern may stem from the non-selectivity of psilocybin and lisuride. Higher doses of psilocybin cause elevated cerebral blood volume that persists over time, whereas the effects of lisuride and 25CN-NBOH return toward baseline. These findings highlight the sensitivity of pharmacological MRI for evaluating drug effects on brain hemodynamics.